EN DE
Watch Taiwan Bio Therapeutics Co., Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Taiwan Bio Therapeutics Co., Ltd (6892) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Taiwan Bio Therapeutics Co., Ltd stock TWD 3.96, price TWD 25.75, that is 84.6% below the price, quality 20 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006892003

TB Taiwan Bio Therapeutics Co., Ltd logo Thin data Nov 9, 2026

Taiwan Bio Therapeutics Co., Ltd

6892 · TWO
Weakest Setup

Our calculation puts a fair price 85% below what the stock costs today.

Expensive Growth (revenue 3y +4.1 %/yr in TWD)
Mixed vs. peers (4/7)
Fair value 3.96 TWD · Strongly overvalued
Quality 20/100
Negative free cash flow
Narrow moat 30/100 · thin data
Thin data
⚠ Dilution
Watch Taiwan Bio Therapeutics Co., Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

30.00 TWD 23.90 TWD Fair Value 3.96 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

11‑month range 23.90 TWD – 30.00 TWD · fair‑value band 2.96 TWD – 5.92 TWD · the 25.75 TWD price screens above the 3.96 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Taiwan Bio Therapeutics Co. in your weekly email

Every Wednesday you see whether Taiwan Bio Therapeutics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Taiwan Bio Therapeutics Co., Ltd., regenerative medicine company, focuses on the development of new cell medicines. It offers medicines for degenerative diseases, cardiovascular diseases, diabetes complications, and autoimmune diseases. The company was founded in 2014 and is based in Taipei, Taiwan.

Stock analysis

Taiwan Bio Therapeutics Co., Ltd (6892) currently trades at 25.75 TWD, while our model-based Fair Value estimate is 3.96 TWD, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 2.96 TWD (bear) to 5.92 TWD (bull), the price of 25.75 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Taiwan Bio Therapeutics Co., Ltd reported revenue of 50.4M TWD in FY2025 versus 27.2M TWD in FY2021, a compound +16.7%/yr. Reported net income was −382M TWD in FY2025.

Key figures

Market cap 2.4B TWD (≈ $73.0M) Micro · EPS (TTM) −4.27 TWD · Return on assets (EBIT) −22.1% (5-year average) · Free cash flow −244M TWD · Net cash 362M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, 6892 screens richer than that median.

Fair Value models

Bear 2.96 TWD Fair Value 3.96 TWD Bull 5.92 TWD
Price 25.75 TWD · Downside -84.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 3.48 TWD 4.66 TWD 6.96 TWD 51
All 1 models by family
Asset-Based
NCAV (Graham) 3.48 TWD 4.66 TWD 6.96 TWD 51

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 20/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 21
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 44
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 28
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−52.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−321.6% (2021) → −762.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6892 screens overvalued: fair value 85% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Taiwan Bio Therapeutics Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside −83.8% · Bottom 25%
Profitability
Return on assets −28.2% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.09× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6892
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6892
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6892
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6892
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6892
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6892
argenx SE ARGX $927.21 $908.40 −2% vs 6892
CSL Limited CSL A$200.77 A$183.04 −9% vs 6892
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6892
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6892

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Taiwan Bio Therapeutics Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Taiwan Bio Therapeutics Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6892

Frequently asked questions

Is Taiwan Bio Therapeutics Co., Ltd (6892) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 3.96 TWD versus a price of 25.75 TWD, about 85% lower (overvalued).
What is the fair value of 6892?
Our model-based fair value for Taiwan Bio Therapeutics Co., Ltd is 3.96 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 25.75 TWD.
What is the quality score of 6892?
Taiwan Bio Therapeutics Co., Ltd has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Taiwan Bio Therapeutics Co., Ltd (6892)?
Our model-based price target is the fair value of 3.96 TWD (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 2.96 TWD, optimistic scenario 5.92 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Taiwan Bio Therapeutics Co., Ltd stock forecast for 2026?
Our models put fair value at 3.96 TWD, about 85% lower versus a price of 25.75 TWD (overvalued). Cautious scenario 2.96 TWD, optimistic scenario 5.92 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Taiwan Bio Therapeutics Co., Ltd (6892)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Taiwan Bio Therapeutics Co., Ltd it is 3.96 TWD per share (as of Nov 9, 2026), against a price of 25.75 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Taiwan Bio Therapeutics Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6892 trades above its calculated fair value: price 25.75 TWD, fair value 3.96 TWD, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6892?
No. The price is what the market pays today (25.75 TWD); the fair value is what the company's own numbers justify (3.96 TWD). For Taiwan Bio Therapeutics Co., Ltd the two are 21.79 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Taiwan Bio Therapeutics Co., Ltd worth?
The market values Taiwan Bio Therapeutics Co., Ltd at about 2.4B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 25.75 TWD; our models calculate a fair value of 3.96 TWD per share.
What do the bullish and bearish scenarios say about 6892?
Our models span a range for Taiwan Bio Therapeutics Co., Ltd: cautious scenario 2.96 TWD, base 3.96 TWD, optimistic 5.92 TWD per share (as of Nov 9, 2026, price 25.75 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 6892 from its 52-week high?
Taiwan Bio Therapeutics Co., Ltd trades at 25.75 TWD, about 14% below its 52-week high of 30.00 TWD and 8% above the low of 23.90 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 3.96 TWD is for.
Which stocks are comparable to Taiwan Bio Therapeutics Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Taiwan Bio Therapeutics Co., Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 25.75 TWD, calculated fair value 3.96 TWD (−85%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6892 calculated?
We run Taiwan Bio Therapeutics Co., Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 3.96 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Taiwan Bio Therapeutics Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Taiwan Bio Therapeutics Co., Ltd (6892)?
The closing price on Nov 9, 2026 was 25.75 TWD. Our model-based fair value is 3.96 TWD, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Taiwan Bio Therapeutics Co., Ltd right now?
The price sits above even our optimistic bull case (5.92 TWD). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.96 TWD to 5.92 TWD) leaves room in how you read the outcome.

Key figures of Taiwan Bio Therapeutics Co., Ltd

How large is the market capitalisation of Taiwan Bio Therapeutics Co., Ltd (6892)?
The market capitalisation of Taiwan Bio Therapeutics Co., Ltd is 2.4B TWD (≈ $73.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Taiwan Bio Therapeutics Co., Ltd (6892)?
Earnings per share at Taiwan Bio Therapeutics Co., Ltd are −4.27 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Taiwan Bio Therapeutics Co., Ltd (6892)?
On an EBIT basis the return on assets of Taiwan Bio Therapeutics Co., Ltd is −22.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Taiwan Bio Therapeutics Co., Ltd (6892) generate?
The free cash flow of Taiwan Bio Therapeutics Co., Ltd is −244M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Taiwan Bio Therapeutics Co., Ltd (6892) hold?
Taiwan Bio Therapeutics Co., Ltd holds more cash than debt, 362M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Taiwan Bio Therapeutics Co., Ltd in the live analysis

One click puts Taiwan Bio Therapeutics Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.